Shares of Immunome, Inc. (NASDAQ:IMNM - Get Free Report) have been assigned an average recommendation of "Buy" from the six ratings firms that are covering the firm, Marketbeat reports. Six analysts have rated the stock with a buy recommendation. The average 1-year target price among brokerages that have covered the stock in the last year is $29.00.
Several research firms have issued reports on IMNM. Piper Sandler reduced their price objective on Immunome from $27.00 to $23.00 and set an "overweight" rating on the stock in a report on Tuesday, August 13th. Wedbush reiterated an "outperform" rating and issued a $33.00 price target on shares of Immunome in a report on Tuesday, August 13th.
Read Our Latest Stock Report on Immunome
In related news, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction on Friday, August 16th. The shares were purchased at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the director now owns 16,615 shares in the company, valued at approximately $231,613.10. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Jack Higgins sold 3,524 shares of the company's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $13.93, for a total value of $49,089.32. Following the completion of the sale, the insider now owns 16,000 shares in the company, valued at $222,880. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Jean Jacques Bienaime bought 7,000 shares of Immunome stock in a transaction on Friday, August 16th. The shares were acquired at an average price of $13.94 per share, for a total transaction of $97,580.00. Following the completion of the acquisition, the director now owns 16,615 shares of the company's stock, valued at approximately $231,613.10. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 8.60% of the company's stock.
Large investors have recently modified their holdings of the business. Quest Partners LLC acquired a new position in Immunome in the 2nd quarter worth $81,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Immunome during the second quarter worth about $97,000. Arizona State Retirement System grew its holdings in shares of Immunome by 9.2% during the second quarter. Arizona State Retirement System now owns 10,862 shares of the company's stock worth $131,000 after buying an additional 918 shares in the last quarter. EntryPoint Capital LLC raised its position in Immunome by 21,864.0% in the 1st quarter. EntryPoint Capital LLC now owns 5,491 shares of the company's stock valued at $136,000 after buying an additional 5,466 shares during the last quarter. Finally, AQR Capital Management LLC lifted its stake in Immunome by 34.6% in the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company's stock valued at $194,000 after acquiring an additional 4,129 shares in the last quarter. 44.58% of the stock is currently owned by institutional investors.
Shares of NASDAQ:IMNM opened at $13.17 on Monday. The business has a fifty day moving average of $14.42 and a 200-day moving average of $15.39. Immunome has a twelve month low of $6.93 and a twelve month high of $30.96. The firm has a market cap of $789.79 million, a PE ratio of -1.74 and a beta of 1.76.
Immunome (NASDAQ:IMNM - Get Free Report) last announced its earnings results on Monday, August 12th. The company reported ($0.49) earnings per share for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.11). Immunome had a negative return on equity of 38.19% and a negative net margin of 2,435.02%. The company had revenue of $2.36 million during the quarter, compared to the consensus estimate of $2.62 million. On average, analysts anticipate that Immunome will post -1.92 EPS for the current fiscal year.
Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Immunome, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunome wasn't on the list.
While Immunome currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.